These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
50. Trial watch: pivotal oncology trials: outlook for Q2 2009. Nehring R Nat Rev Drug Discov; 2009 Apr; 8(4):266. PubMed ID: 19337264 [No Abstract] [Full Text] [Related]
51. Statistical and trial design considerations in central nervous system prophylaxis studies. Smith JA; Glantz M Semin Oncol; 2009 Aug; 36(4 Suppl 2):S69-76. PubMed ID: 19660685 [TBL] [Abstract][Full Text] [Related]
52. Immunotherapy for malignant melanoma--tracing Ariadne's thread through the labyrinth. Grange JM; Krone B; Stanford JL Eur J Cancer; 2009 Sep; 45(13):2266-73. PubMed ID: 19497734 [TBL] [Abstract][Full Text] [Related]
53. Immunotherapeutics in development for prostate cancer. Harzstark AL; Small EJ Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474 [TBL] [Abstract][Full Text] [Related]
54. The use of dendritic cells in cancer therapy. Jefford M; Maraskovsky E; Cebon J; Davis ID Lancet Oncol; 2001 Jun; 2(6):343-53. PubMed ID: 11905751 [TBL] [Abstract][Full Text] [Related]
55. No end in sight for German misconduct probe. Kerstholt M Nature; 2002 May; 417(6884):6. PubMed ID: 11986633 [No Abstract] [Full Text] [Related]
60. Cancer prevention: from 1727 to milestones of the past 100 years. Lippman SM; Hawk ET Cancer Res; 2009 Jul; 69(13):5269-84. PubMed ID: 19491253 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]